<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00649389</url>
  </required_header>
  <id_info>
    <org_study_id>CS8635-A-U301</org_study_id>
    <nct_id>NCT00649389</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension</brief_title>
  <official_title>A Randomized, Double-Blind, Parallel Group Study Evaluating the Efficacy and Safety of Co-Administration of a Triple Combination Therapy of Olmesartan Medoxomil, Amlodipine Besylate and Hydrochlorothiazide in Subjects With Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Daiichi Sankyo, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Daiichi Sankyo, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effectiveness of four different strength combinations of three approved
      anti-hypertension therapies (olmesartan medoxomil, amlodipine, and hydrochlorothiazide) for
      lowering blood pressure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).</measure>
    <time_frame>baseline to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Reached Blood Pressure Goal (&lt;140/90 mmHg; &lt;130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks</measure>
    <time_frame>Baseline to 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination</measure>
    <time_frame>Baseline to 12 weeks or early termination</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Seated Systolic Blood Pressure From Baseline to Week 12</measure>
    <time_frame>Baseline to week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">2500</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>OM40/AML10</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>olmesartan medoxomil 40mg and amlodipine 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OM40/HCTZ25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olmesartan medoxomil 40mg and hydrochlorothiazide 25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AML10/HCTZ25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>amlodipine 10mg and hydrochlorothiazide 25mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OM40/AML10/HCTZ25</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>olmesartan medoxomil 40mg, amlodipine 10mg, and hydrochlorothiazide 25mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan medoxomil</intervention_name>
    <description>40mg olmesartan medoxomil</description>
    <arm_group_label>OM40/AML10</arm_group_label>
    <arm_group_label>OM40/HCTZ25</arm_group_label>
    <arm_group_label>OM40/AML10/HCTZ25</arm_group_label>
    <other_name>Benicar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine</intervention_name>
    <description>Amlodipine 10mg</description>
    <arm_group_label>OM40/AML10</arm_group_label>
    <arm_group_label>AML10/HCTZ25</arm_group_label>
    <arm_group_label>OM40/AML10/HCTZ25</arm_group_label>
    <other_name>Norvasc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>Hydrochlorothiazide 25mg</description>
    <arm_group_label>OM40/HCTZ25</arm_group_label>
    <arm_group_label>AML10/HCTZ25</arm_group_label>
    <arm_group_label>OM40/AML10/HCTZ25</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Demonstrable hypertension defined as mean sitting trough cuff blood pressure ≥ 140/100
             mmHg (SeSBP ≥ 140 mmHg and SeDBP ≥ 100mmHg) or mean sitting trough cuff BP ≥ 160/90
             mmHg (SeSBP ≥ 160 mmHg and SeDBP ≥ 90mmHg).

          -  Male or female newly diagnosed hypertensive subjects or currently on hypertension
             medication.

               -  Negative urine pregnancy test at screening

               -  Not lactating

               -  Do not plan to become pregnant during the study

               -  Will practice birth control throughout the study by the following: oral or patch
                  contraceptive, injectable or implantable contraceptive medication, intrauterine
                  device, diaphragm or female condom plus spermicide

                    -  Non childbearing potential must be classified by one of the following
                       criteria

                    -  Had a hysterectomy or tubal ligation at least 6 months prior to consent

                    -  Has been postmenopausal for a least 1 year

        Exclusion Criteria:

          -  Mean sitting trough cuff DBP &lt;90 mmHg or mean sitting trough cuff SBP &lt;140 mmHg (off
             antihypertensive medication).

          -  Subjects with uncontrolled hypertension taking multiple antihypertensive therapies (at
             the discretion of the investigator).

          -  Signs or symptoms which could exacerbate the occurrence of hypotension such as volume
             and salt depletion.

          -  History of hypertensive encephalopathy, stroke or transient ischemic attack (TIA).

          -  Participation in another clinical trial involving an investigational drug within one
             month prior to screening.

          -  History of myocardial infarction, percutaneous transluminal coronary
             revascularization, coronary artery bypass graft, and/or unstable angina within the
             past 6 months.

          -  Any history of New York Heart Association Class III or IV congestive heart failure
             (CHF). A history of New York Heart Association Class I or II CHF may be exclusionary
             at the discretion of the investigator.

          -  History of secondary hypertension including renal disease, pheochromocytoma, or
             Cushing's syndrome.

          -  Uncorrected coarctation of the aorta, bilateral renal artery stenosis, or unilateral
             renal artery stenosis in a solitary kidney.

          -  Evidence of symptomatic resting bradycardia.

          -  Evidence of hemodynamically significant cardiac valvular disease.

          -  Presence of heart block greater than first degree atrioventricular block, chronic
             atrial fibrillation or flutter.

          -  Uncontrolled Type I or Type II diabetes defined as HbA1c &gt;9.0%. Diabetics must have
             documentation of HbA1c within 6 months of the Screening Visit. Undocumented subjects
             must have their HbA1c assessed prior to randomization. Note: Subjects with Type I or
             Type II diabetes controlled with insulin, diet or oral hypoglycemic agents on a stable
             dose for at least 30 days may be included.

          -  Evidence of liver disease as indicated by ALT and AST and/or total bilirubin &gt;3 times
             the upper limit of normal.

          -  Severe renal insufficiency defined as a creatinine clearance (based on the
             Cockcroft-Gault formula) of &lt;30 mL/min.

          -  Clinically significant laboratory elevations at Visit 1 that compromise subject
             safety, based on the investigator's judgment. Consideration should take into account
             the potential laboratory effects of the component blinded therapies.

          -  Positive for any one of the following tests: hepatitis B surface antigen, hepatitis C
             antibody (confirmed by radio immunobinding assay, RIBA) or HIV antibody (confirmed by
             western blot assay).

          -  Subjects with malignancy during the past 2 years excluding squamous cell or basal cell
             carcinoma of the skin.

          -  Known allergy to any of the medications used in the study.

          -  Subjects who require or are taking any concomitant medication, which may interfere
             with the objectives of the study (Refer to Section 5.2 for a listing of excluded
             medications).

          -  Pregnant or lactating females.

          -  Current history of drug or alcohol abuse.

          -  A subject with any medical condition, which in the judgment of the Investigator would
             jeopardize the evaluation of efficacy or safety and/or constitute a significant safety
             risk to the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbiana</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gulf Shores</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hoover</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Montgomery</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Muscle Shoals</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscumbia</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Goodyear</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Havasu City</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tuscon</city>
        <state>Arizona</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jonesboro</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Little Rock</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Searcy</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burbank</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Carmichael</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chino</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Huntington Park</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Los Gatos</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merced</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>National City</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orange</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Ana</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temecula</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Palm Beach</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westlake Village</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Golden</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pueblo</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheat Ridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wheatridge</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Danbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stamford</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Trumbull</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boynton Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooksville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cape Coral</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Crystal River</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Deland</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Delray Beach</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Dunellon</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jupiter</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Merritt Island</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>W. Bradenton</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suwanee</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waycross</city>
        <state>Georgia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Gurnee</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Libertyville</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Evansville</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Newton</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shawnee</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madisonville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Sterling</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Munfordville</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paducah</city>
        <state>Kentucky</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kenner</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Charles</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Shreveport</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elkridge</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oxon Hill</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brickton</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Haverhill</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West yarmouth</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Benzonia</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Paw Paw</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Traverse City</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waterford</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Brooklyn Center</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chaska</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Paul</city>
        <state>Minnesota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Olive Branch</city>
        <state>Mississippi</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Florissant</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Missoula</city>
        <state>Montana</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Broken Bow</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>North Platte</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Voorhees</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Manlius</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mineola</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westfield</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Calabash</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Statesville</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tabor City</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austintown</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Euclid</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Franklin</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kettering</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lyndhurst</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Marion</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Mt. Gilead</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Wadsworth</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Westlake</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norman</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma CIty</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Beaver</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bensalem</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Downingtown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Erie</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Harleysville</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Jersey Shore</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Penndel</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cranston</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>East Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Murrells Inlet</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orangeburg</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rapid City</city>
        <state>South Dakota</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bristol</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Fayetteville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Tazewell</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tullahoma</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bedford</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Corpus Christi</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Hurst</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lake Jackson</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midland</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Round Rock</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Spring</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Temple</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Bountiful</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Magna</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Midvale</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sandy</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Saratoga Springs</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>West Jordan</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Suffolk</city>
        <state>Virginia</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Federal Way</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Lakewood</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Kenosha</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ciales</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Guayama</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Ponce</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Rio Piedras</city>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <results_first_submitted>August 9, 2010</results_first_submitted>
  <results_first_submitted_qc>August 9, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 1, 2010</results_first_posted>
  <disposition_first_submitted>April 7, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>April 7, 2010</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 9, 2010</disposition_first_posted>
  <last_update_submitted>August 31, 2010</last_update_submitted>
  <last_update_submitted_qc>August 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 8, 2010</last_update_posted>
  <responsible_party>
    <name_title>Executive Director Clinical Development</name_title>
    <organization>Daiichi Sankyo Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject first visit 12 May 2008. Last subject last follow-up 27 Feb 2009. 317 sites in USA and Puerto Rico. Planned: 2400 subjects (600 per treatment arm). Enrolled: 6724 subjects. Randomized: 2492 subjects.</recruitment_details>
      <pre_assignment_details>Duration of the study was 57 weeks with 52 weeks of treatment. This included 3-week stabilization/washout (Period I), 12-week double blind treatment (Period II), 40 week open label treatment (Period III), and 2-week post treatment follow-up (Period IV).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>OM40/AML10</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily.</description>
        </group>
        <group group_id="P2">
          <title>OM40/HCTZ25</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
        </group>
        <group group_id="P3">
          <title>AML10/HCTZ25</title>
          <description>Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
        </group>
        <group group_id="P4">
          <title>OM40/AML10/HCTZ25</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="628"/>
                <participants group_id="P2" count="637"/>
                <participants group_id="P3" count="600"/>
                <participants group_id="P4" count="627"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="557"/>
                <participants group_id="P2" count="531"/>
                <participants group_id="P3" count="512"/>
                <participants group_id="P4" count="516"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="106"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="111"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="38"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="17"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="21"/>
                <participants group_id="P3" count="19"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>OM40/AML10</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily.</description>
        </group>
        <group group_id="B2">
          <title>OM40/HCTZ25</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
        </group>
        <group group_id="B3">
          <title>AML10/HCTZ25</title>
          <description>Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
        </group>
        <group group_id="B4">
          <title>OM40/AML10/HCTZ25</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="628"/>
            <count group_id="B2" value="637"/>
            <count group_id="B3" value="600"/>
            <count group_id="B4" value="627"/>
            <count group_id="B5" value="2492"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="508"/>
                    <measurement group_id="B2" value="505"/>
                    <measurement group_id="B3" value="504"/>
                    <measurement group_id="B4" value="504"/>
                    <measurement group_id="B5" value="2021"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="132"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="123"/>
                    <measurement group_id="B5" value="471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.1" spread="10.93"/>
                    <measurement group_id="B2" value="55.9" spread="10.78"/>
                    <measurement group_id="B3" value="54.6" spread="10.82"/>
                    <measurement group_id="B4" value="54.7" spread="11.22"/>
                    <measurement group_id="B5" value="55.1" spread="10.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="303"/>
                    <measurement group_id="B2" value="298"/>
                    <measurement group_id="B3" value="266"/>
                    <measurement group_id="B4" value="307"/>
                    <measurement group_id="B5" value="1174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="339"/>
                    <measurement group_id="B3" value="334"/>
                    <measurement group_id="B4" value="320"/>
                    <measurement group_id="B5" value="1318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Race of participants as selected by participant. Participants were allowed to choose more than one race category; therefore, the total for an arm may be greater than the number of participants</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian/Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                    <measurement group_id="B5" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hawaiian/Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black/African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="181"/>
                    <measurement group_id="B2" value="200"/>
                    <measurement group_id="B3" value="192"/>
                    <measurement group_id="B4" value="184"/>
                    <measurement group_id="B5" value="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="431"/>
                    <measurement group_id="B2" value="421"/>
                    <measurement group_id="B3" value="391"/>
                    <measurement group_id="B4" value="415"/>
                    <measurement group_id="B5" value="1658"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Status</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Diabetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="100"/>
                    <measurement group_id="B2" value="99"/>
                    <measurement group_id="B3" value="92"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="387"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not diabetic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="528"/>
                    <measurement group_id="B2" value="538"/>
                    <measurement group_id="B3" value="508"/>
                    <measurement group_id="B4" value="531"/>
                    <measurement group_id="B5" value="2105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.9" spread="22.65"/>
                    <measurement group_id="B2" value="96.1" spread="22.55"/>
                    <measurement group_id="B3" value="96.1" spread="23.41"/>
                    <measurement group_id="B4" value="96.0" spread="23.24"/>
                    <measurement group_id="B5" value="96.0" spread="22.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Less than 30 kg/m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="238"/>
                    <measurement group_id="B3" value="230"/>
                    <measurement group_id="B4" value="240"/>
                    <measurement group_id="B5" value="937"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Greater than or equal to 30 kg/m2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="399"/>
                    <measurement group_id="B2" value="399"/>
                    <measurement group_id="B3" value="370"/>
                    <measurement group_id="B4" value="387"/>
                    <measurement group_id="B5" value="1555"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of hypertension</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.12" spread="9.865"/>
                    <measurement group_id="B2" value="10.34" spread="9.826"/>
                    <measurement group_id="B3" value="9.73" spread="8.983"/>
                    <measurement group_id="B4" value="9.54" spread="9.558"/>
                    <measurement group_id="B5" value="9.94" spread="9.571"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).</title>
        <time_frame>baseline to 12 weeks</time_frame>
        <population>The full analysis set consists of subjects who received at least 1 dose of study medication and had a baseline and at least one post-dose assessment of SeDBP</population>
        <group_list>
          <group group_id="O1">
            <title>OM40/AML10</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>OM40/HCTZ25</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>AML10/HCTZ25</title>
            <description>Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>OM40/AML10/HCTZ25</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).</title>
          <population>The full analysis set consists of subjects who received at least 1 dose of study medication and had a baseline and at least one post-dose assessment of SeDBP</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="627"/>
                <count group_id="O3" value="593"/>
                <count group_id="O4" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.8" spread="9.47"/>
                    <measurement group_id="O2" value="-16.5" spread="10.84"/>
                    <measurement group_id="O3" value="-14.8" spread="8.78"/>
                    <measurement group_id="O4" value="-21.5" spread="10.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Who Reached Blood Pressure Goal (&lt;140/90 mmHg; &lt;130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks</title>
        <time_frame>Baseline to 12 weeks</time_frame>
        <population>The full analysis set consists of subjects who received at least 1 dose of study medication and had a baseline and at least one post-dose assessment of seated diastolic blood pressure</population>
        <group_list>
          <group group_id="O1">
            <title>OM40/AML10</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>OM40/HCTZ25</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>AML10/HCTZ25</title>
            <description>Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>OM40/AML10/HCTZ25</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Reached Blood Pressure Goal (&lt;140/90 mmHg; &lt;130/80 mmHg for Subjects With Diabetes, Chronic Renal Disease, or Chronic Cardiovascular Disease)by 12 Weeks</title>
          <population>The full analysis set consists of subjects who received at least 1 dose of study medication and had a baseline and at least one post-dose assessment of seated diastolic blood pressure</population>
          <units>Percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="627"/>
                <count group_id="O3" value="593"/>
                <count group_id="O4" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.0"/>
                    <measurement group_id="O2" value="46.6"/>
                    <measurement group_id="O3" value="34.9"/>
                    <measurement group_id="O4" value="64.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Each p-value was obtained from individual Cochran-Mantel-Haenszel tests stratified by age group, race group, and diabetic status comparing the triple combination therapy to each dual combination.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Each p-value was obtained from individual Cochran-Mantel-Haenszel tests stratified by age group, race group, and diabetic status comparing the triple combination therapy to each dual combination.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Each p-value was obtained from individual Cochran-Mantel-Haenszel tests stratified by age group, race group, and diabetic status comparing the triple combination therapy to each dual combination.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination</title>
        <time_frame>Baseline to 12 weeks or early termination</time_frame>
        <population>The ABPM Analysis Set included 440 subjects who provided consent to participate in the ABPM sub-study and who were to provide ABPM measurements prior to and after randomization. Those analyzed is the number who had values at both baseline and 12 weeks or early termination</population>
        <group_list>
          <group group_id="O1">
            <title>OM40/AML10</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>OM40/HCTZ25</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>AML10/HCTZ25</title>
            <description>Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>OM40/AML10/HCTZ25</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean 24-hour Ambulatory Blood Pressure From Baseline to Week 12 or Early Termination</title>
          <population>The ABPM Analysis Set included 440 subjects who provided consent to participate in the ABPM sub-study and who were to provide ABPM measurements prior to and after randomization. Those analyzed is the number who had values at both baseline and 12 weeks or early termination</population>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="101"/>
                <count group_id="O3" value="83"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Diastolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.9" spread="8.09"/>
                    <measurement group_id="O2" value="-14.5" spread="8.73"/>
                    <measurement group_id="O3" value="-10.7" spread="7.46"/>
                    <measurement group_id="O4" value="-18.0" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic blood pressure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-23.5" spread="11.80"/>
                    <measurement group_id="O2" value="-23.9" spread="13.10"/>
                    <measurement group_id="O3" value="-18.5" spread="10.67"/>
                    <measurement group_id="O4" value="-30.3" spread="13.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Diastolic blood pressure: All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Diastolic blood pressure: All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Diastolic blood pressure: All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Systolic blood pressure: All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Systolic blood pressure: All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Systolic blood pressure: All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Seated Systolic Blood Pressure From Baseline to Week 12</title>
        <time_frame>Baseline to week 12</time_frame>
        <group_list>
          <group group_id="O1">
            <title>OM40/AML10</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily.</description>
          </group>
          <group group_id="O2">
            <title>OM40/HCTZ25</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
          </group>
          <group group_id="O3">
            <title>AML10/HCTZ25</title>
            <description>Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
          </group>
          <group group_id="O4">
            <title>OM40/AML10/HCTZ25</title>
            <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Seated Systolic Blood Pressure From Baseline to Week 12</title>
          <units>mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="627"/>
                <count group_id="O3" value="593"/>
                <count group_id="O4" value="614"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.1" spread="15.44"/>
                    <measurement group_id="O2" value="-31.2" spread="18.58"/>
                    <measurement group_id="O3" value="-28.9" spread="15.12"/>
                    <measurement group_id="O4" value="-38.1" spread="17.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>All treatment comparisons were calculated as OM40/AML10/HCTZ25 minus the respective dual combination treatment group. Least-squares mean differences, SEs, and 2-sided p-values were obtained from an ANCOVA model with baseline blood pressure as a covariate, and fixed effects of treatment, age group, race group, and diabetic status.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Safety was assessed at all study visits. Variables included adverse events, clinical laboratory tests, vital signs, ECGs, and physical examinations. The assessment of causality was based on the investigator's judgment.</desc>
      <group_list>
        <group group_id="E1">
          <title>OM40/AML10</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg tablets once daily.</description>
        </group>
        <group group_id="E2">
          <title>OM40/HCTZ25</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
        </group>
        <group group_id="E3">
          <title>AML10/HCTZ25</title>
          <description>Double blind treatment Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg tablets once daily.</description>
        </group>
        <group group_id="E4">
          <title>OM40/AML10/HCTZ25</title>
          <description>Double blind treatment olmesartan medoxomil (OM) 40 mg, Amlodipine (AML) 10 mg, Hydrochlorothiazide (HCTZ) 25 mg, tablets once daily.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>pulmonary artery atresia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>gastrointstial haemhorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>hiatus hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>rectal haemhorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 11.0">appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>lobar pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>hip fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>vertebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>intervertebral disc degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovasular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>peroneal nerve palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute prerenal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="210" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="210" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="212" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="237" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>edema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="44" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="36" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="25" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="574"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="596"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="580"/>
                <counts group_id="E3" subjects_affected="33" subjects_at_risk="552"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="574"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Study site may not publish results of study until after coordinated multicenter publication has been submitted for publication or one year after study has ended, whichever occurs first. Therefore, study site will have the opportunity to publish results of study, provided that Daiichi Sankyo has had the opportunity to review and comment on study site’s proposed publication prior to being submitted for publication with advice of company patent council and in accord with subject protection needs.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Howard Kessler</name_or_title>
      <organization>Daiichi Sankyo</organization>
      <phone>732-590-5032</phone>
      <email>hmkessler@dsi.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

